

Sarcomatrix Selected as Finalist for Prestigious Start-Up Stadium at BIO International Convention 2025

BOSTON, MA, UNITED STATES, May 29, 2025 /EINPresswire.com/ --

[Sarcomatrix Therapeutics Corp.](#), a

pioneering biotech company

developing oral, mutation-agnostic

therapies for muscle-wasting diseases, has been selected as a finalist for the highly competitive Start-Up Stadium at the 2025 BIO International Convention in Boston, Massachusetts. The event, hosted by the Biotechnology Innovation Organization (BIO), showcases the most promising early-stage biotech companies from around the globe.



SARCOMATRIX
Sarcomatrix Therapeutics

“

We are honored to present our progress at Start-Up Stadium and look forward to engaging with investors and partners who share our vision for transforming muscle disease treatment.”

*David Craig, Chief Executive
Officer of Sarcomatrix
Therapeutics Corp.*

Each year, Start-Up Stadium identifies a select group of emerging innovators—less than 40 from hundreds of global applicants—to present their novel technologies to a panel of seasoned investor judges, industry executives, and strategic partners. Finalists are chosen based on scientific innovation, market potential, capital efficiency, and the strength of their leadership teams.

Sarcomatrix earned its place through a rigorous selection process, highlighting its lead candidate S-969—a daily oral small molecule that targets key integrin pathways implicated in Duchenne Muscular Dystrophy (DMD),

cachexia, and age-related sarcopenia. With potency, a clean safety profile, and preclinical data supported by NIH’s IND-enabling gap analysis, S-969 exemplifies Sarcomatrix’s commitment to delivering scalable, patient-friendly therapies to underserved populations.

“Our selection affirms the urgency and potential of Sarcomatrix’s mission,” said David Craig, Chief Executive Officer. “We are honored to present our progress at Start-Up Stadium and look forward to engaging with investors and partners who share our vision for transforming muscle disease treatment.”

Sarcomatrix will present on Wednesday, June 18, 2025 at 1:12P ET, during the 13-minute

showcase slot, joining an elite cohort of companies aligned with BIO's strategic themes, including orphan diseases, platform innovation, and global impact.

For more information, visit www.sarcomatrix.com or contact press@sarcomatrix.com.

About Sarcomatrix Therapeutics:

Sarcomatrix Therapeutics is a privately held biopharmaceutical company advancing a portfolio of novel oral therapies to restore muscle integrity in patients affected by degenerative muscle diseases. Leveraging integrin biology and proprietary chemistry, the company's pipeline is designed to provide convenient, safe, and effective solutions across multiple muscle-wasting conditions. Sarcomatrix is currently preparing for a first-in-human clinical trial of its lead program, S-969, in early 2026.

Media Contact:

Madelyn De Los Santos
Putnam Insights
madelyn@putnaminsights.com

This press release can be viewed online at: <https://www.einpresswire.com/article/817201352>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.